- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510128
Evaluation of the Effectiveness of a Protocol for the Management of Female Functional Urinary Signs (PharmaCyst')
Evaluation of the Effectiveness of the Application of a Protocol for the Management of Female Functional Urinary Signs in French Community Pharmacies
Every year, between 4 and 6 million French people are affected by a urinary infection; the vast majority of these are women. Although the diagnosis of an uncomplicated urinary tract infection is simple to make, it requires prompt medical management to relieve the symptoms. The lack of immediate of a physician can slow down the management of patients affected by this condition, and lead to an inappropriate referral of patients to the emergency services.
Because of their wide availability, accessibility, and geographical distribution throughout the country, pharmacists are primary health care professionals who are regularly called upon to respond to patients with this type of infection.
A national protocol exists in France, but it is very difficult to apply. The PharmaCyst' study aims to evaluate its application in community pharmacies.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Arthur Piraux, PharmD, PhD
- Phone Number: +33 0241226732
- Email: arthur.piraux@univ-angers.fr
Study Contact Backup
- Name: Anthéa Loiez
- Phone Number: +33 0241353637
- Email: anthea.loiez@chu-angers.fr
Study Locations
-
-
-
Bourgneuf-en-retz, France, 44580
- Recruiting
- Pharmacie du Pays De Retz
-
Contact:
- Benjamin CORCELLE
-
Bretignolles-sur-Mer, France
- Recruiting
- Pharmacie du Clocher
-
Contact:
- Vincent BARRETEAU
-
Brûlon, France
- Recruiting
- Pharmacie de Brûlon
-
Contact:
- Sandrine GASNIER
-
Chantonnay, France
- Recruiting
- Pharmacie du Centre
-
Contact:
- Nathalie BRETAUD
-
Chemazé, France
- Recruiting
- Pharmacie Degueille
-
Contact:
- Benoît DEGUEILLE
-
Chemillé-Melay, France, 49120
- Recruiting
- Pharmacie Nicolleau-Dilé
-
Contact:
- Nathalie Dilé
-
Craon, France
- Recruiting
- Pharmacie des Halles
-
Contact:
- Marion PARIS
-
Fontenay-le-Comte, France
- Recruiting
- Pharmacie Principale Harel
-
Contact:
- Catherine HAREL
-
La Ferté-Bernard, France
- Recruiting
- Pharmacie de la Place
-
Contact:
- Yann LESAINT
-
Le Mans, France
- Recruiting
- Pharmacie de Gazonfier
-
Contact:
- Pierre BRUGUIERE
-
Le Mans, France
- Recruiting
- Pharmacie de la Pointe
-
Contact:
- Antoine MACE
-
Le May-sur-Èvre, France
- Recruiting
- Pharmacie du Centre
-
Contact:
- Isabelle BARDOUIL
-
Les Sables-d'Olonne, France
- Recruiting
- Pharmacie Leeuws-Guilloton
-
Contact:
- Louis-Marie LEEUWS
-
Mesquer, France
- Recruiting
- Pharmacie de la Presqu'île
-
Contact:
- Thierry Guyon
-
Mûrs-Erigné, France
- Recruiting
- Pharmacie du Louet
-
Contact:
- Aurélie HERLIN
-
Noyen-sur-Sarthe, France
- Recruiting
- Pharmacie Flotté
-
Contact:
- Camille FLOTTE
-
Nozay, France
- Recruiting
- Pharmacie des Arcades
-
Contact:
- Philippe GRANDON
-
Pont Saint-martin, France
- Recruiting
- Pharmacie de la Place
-
Contact:
- Maël DRAPEAU
-
Roeze-sur-sarthe, France
- Recruiting
- Pharmacie Deroche
-
Contact:
- Sophie DEROCHE
-
Saint-Philbert-de-Bouaine, France
- Recruiting
- Pharmacie des Glycines
-
Contact:
- Fanny THOMAS
-
Sainte-anne Sur Brivet, France
- Recruiting
- Pharmacie Llacuna
-
Contact:
- Maud LLACUNA
-
Saumur, France
- Recruiting
- Pharmacie du Chemin Vert
-
Contact:
- Caroline DAVID
-
Soucelles, France
- Recruiting
- Pharmacie des Rives du Loir
-
Contact:
- Loïc MOISAN
-
Sougé-le-Ganelon, France
- Recruiting
- Pharmacie de la Source
-
Contact:
- Christelle GAUVRIT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female
- Age ≥ 18 and <65 years
Patient with less than 3 days of simple urinary tract infection symptoms:
- Burning, pain on urination
- Dysuria
- Pollakiuria
- Urinary urgency
- Patient affiliated or beneficiary of a social insurance
- Patient having signed an informed consent.
Exclusion Criteria:
- More than 3 cystitis in the last 12 months;
- Last cystitis less than 15 days old;
- Presence of fever;
- Presence of back pain;
- Presence of a functional or organic anomaly of the urinary tract (bladder residue, vesico-ureteral reflux, lithiasis, tumor);
- Pruritus or vaginal discharge;
- Vomiting, diarrhea, diffuse abdominal pain;
- Risk factors for C3G-resistant enterobacteria infection (grade B):
- Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within the previous 3 months;
- A nosocomial or healthcare-associated infection;
- A history of colonization or infection with C3G-resistant enterobacteria within the last 3 months;
- A trip to a foreign country within the last 3 months in known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean basin);
- Hospitalization within 3 months;
- Hospitalization within 6 months for UTI;
- Known severe renal insufficiency (creatinine clearance < 30 mL/min);
- Severe immunosuppression or immunosuppressive treatments;
- Contraindications to drugs planned for experimental management (pivmecillinam and fosfomycin) or combination of drugs not recommended;
- Pregnant women (confirmed or suspected pregnancy), breastfeeding women or women in labour;
- Person deprived of liberty by judicial or administrative decision;
- Person under forced psychiatric care;
- Person admitted to a health or social institution for purposes other than research;
- Person subject to a legal protection measure;
- A person who is unable to give consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Management with the protocol
Patients who participate in the study in the experimental arm benefit from an adapted management, which falls under the application of the national cooperation protocol. This management may lead to the dispensing of an antibiotic by the pharmacist himself. |
When a patient comes to the pharmacy with signs of urinary burning, the following will follow:
If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made. |
No Intervention: Standard care
Patients participating in the study in the control arm will benefit from a management comparable to the current one. In addition to a reminder of the hygienic and dietary rules by the pharmacist, the patient may be offered a drug indicated for improving urinary comfort. The pharmacist should also remind the patient that she can consult a doctor, especially in case of non relief or aggravation of symptoms. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The evolution of the symptoms at D3
Time Frame: Enrollment, Day 3
|
Difference in the score from the first part of the Acute Cystitis Symptome Score questionnaire.
The minimum value is 0 and the maximun value is 18.
A higher score mean worse outcome
|
Enrollment, Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The evolution of the symptoms at D10
Time Frame: Enrollment, Day 10
|
Difference in the score from the first part of the Acute Cystitis Symptome Score questionnaire.
The minimum value is 0 and the maximun value is 18.
A higher score mean worse outcome
|
Enrollment, Day 10
|
Performing a urine dipstick
Time Frame: Enrollment, Day 3, Day 10
|
Number of urine dipstick performed
|
Enrollment, Day 3, Day 10
|
Performing a urine culture
Time Frame: At 3 days and 10 days
|
Number of urine culture performed
|
At 3 days and 10 days
|
Recurrence of a urinary tract infection within 3 months (M3)
Time Frame: At 3 months
|
Number of cystitis encountered
|
At 3 months
|
Use of a medical consultation or an emergency service
Time Frame: At 3 days
|
Number of consultations provided
|
At 3 days
|
Use of a medical consultation or an emergency service
Time Frame: At 10 days
|
Nature of consultations provided
|
At 10 days
|
Taking medication to relieve the symptoms of the infection
Time Frame: Enrollment,
|
Number of medication used
|
Enrollment,
|
Taking medication to relieve the symptoms of the infection
Time Frame: Day 3,
|
Nature of medication used
|
Day 3,
|
Taking medication to relieve the symptoms of the infection
Time Frame: Day 10
|
Nature of medication used
|
Day 10
|
Occurrence of an adverse event at D3 and D10
Time Frame: At 10 days
|
Number of adverse events
|
At 10 days
|
Occurrence of an adverse event at D3 and D10
Time Frame: At 3 days
|
Nature of adverse events
|
At 3 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' satisfaction
Time Frame: At 10 days
|
Satisfaction measured by a Likert scale.
The minimum value is 0 and the maximun value is 27.
A higher score mean good outcome
|
At 10 days
|
Pharmacists' satisfaction
Time Frame: through study completion, an average of 12 months
|
Satisfaction measured by a Likert scale.
The minimum value is 0 and the maximun value is 51.
A higher score mean good outcome
|
through study completion, an average of 12 months
|
Pharmacists' experience
Time Frame: through study completion, an average of 12 months
|
We will conduct semi-structured interviews with investigator pharmacyst who want's it We will explore Pharmacists' experience on the clinical research participation, including its Strengths, Weaknesses, Opportunities, and Threats.
|
through study completion, an average of 12 months
|
Patients' care overall satisfaction
Time Frame: At 10 days
|
Satisfaction measured by a Likert scale.
The minimum value is 0 and the maximun value is 10.
A higher score mean good outcome
|
At 10 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sébastien Faure, Professor, University of Angers
- Study Director: Aline Ramond-Roquin, Professor, University of Angers
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 49RC22_0240
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystitis Acute
-
University of OsloLund University; University of Copenhagen; University of BergenCompletedAcute Cystitis (Excl in Pregnancy)Norway
-
Soonchunhyang University HospitalCompletedAcute CystitisKorea, Republic of
-
University Hospital, RouenCompletedAcute Uncomplicated Bacterial CystitisFrance
-
Asan Medical CenterCompletedChronic Interstitial CystitisKorea, Republic of
-
St. Louis UniversityTerminated
-
St. Louis UniversityCompletedInterstitial Cystitis
-
Northwell HealthWithdrawnInterstitial CystitisUnited States
-
CAMC Health SystemCompletedInterstitial CystitisUnited States
-
UroGen Pharma Ltd.CompletedInterstitial Cystitis | ICIsrael
Clinical Trials on Pharmacist management
-
University of Louisiana MonroeOchsner Health SystemCompletedHypertension | Blood PressureUnited States
-
Zahava Rosenberg-YungerCompletedUncontrolled Asthma
-
Advantage Health Physician NetworkDoran Foundation; Michigan Pharmacist Foundation; Priority Health; Western Michigan...Completed
-
University of California, San DiegoCompletedHypertensionUnited States
-
Queen's University, BelfastCompletedPatients at High Risk of Medicine-related ProblemsUnited Kingdom
-
University of Illinois at ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Shaoxing Maternity and Child Health Care HospitalRecruiting
-
The Leeds Teaching Hospitals NHS TrustCompleted
-
Providence Health & ServicesTerminated
-
Brigham and Women's HospitalCompletedDiabetes MellitusUnited States